Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma ; volume:13 ; number:1 ; day:16 ; month:1 ; year:2013 ; pages:1-8 ; date:12.2013
BMC cancer ; 13, Heft 1 (16.1.2013), 1-8, 12.2013
- Urheber
-
Federico, Rea
- Beteiligte Personen und Organisationen
-
Adolfo, Favaretto
Giuseppe, Marulli
Lorenzo, Spaggiari
Martino, DePas Tommaso
Anna, Ceribelli
Adriano, Paccagnella
Gino, Crivellari
Francesca, Russo
Matteo, Ceccarelli
Gbenga, Kazeem
Paolo, Marchi
Francesco, Facciolo
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-13-22
- URN
-
urn:nbn:de:1111-2016030410886
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Federico, Rea
- Adolfo, Favaretto
- Giuseppe, Marulli
- Lorenzo, Spaggiari
- Martino, DePas Tommaso
- Anna, Ceribelli
- Adriano, Paccagnella
- Gino, Crivellari
- Francesca, Russo
- Matteo, Ceccarelli
- Gbenga, Kazeem
- Paolo, Marchi
- Francesco, Facciolo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial)
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity
Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
Molecular biological analysis of malignant pleural mesothelioma
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity
Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial)
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity
Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
Molecular biological analysis of malignant pleural mesothelioma
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity
Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial)
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity
Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
Molecular biological analysis of malignant pleural mesothelioma
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience